ClinicalTrials.gg
CompletedNCT00256126Updated Jun 26, 2018Results posted

Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®

A Phase 4 interventional study of Saizen and Saizen in Growth Hormone Deficiency and Turner Syndrome, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 13 sites in 13 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2018-06-26.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled May 2005, registered Nov 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
318
Allocation
Non-randomized
Ages
2 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.

Enrollment
8th of 60
318 · median 66
Started
2005
with 4 others
Phase 4
19 of 60
none open now
Registered
16th of 60
by date
Lead sponsor
4 of 60
Merck KGaA, Darmstadt, Germany

Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 8th largest by enrollment, is one of 5 that started in 2005, is one of 19 in phase 4, and was the 16th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Human Growth Hormone

Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 2 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, or all of them as a file.
02

Study summary

The study aims at identifying the predictive markers after one month of Saizen therapy in Growth Hormone Deficiency (GHD) and Turner Syndrome children.

03

Conditions studied

  • Growth Hormone Deficiency
  • Turner Syndrome
04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • One of the following diagnoses and candidacy for SAIZEN® therapy:

A) GHD: documented pre-established diagnosis of GHD with a growth hormone (GH) peak response of \<10 microgram per liter (mcg/L) with 2 GH stimulation tests, without priming with oestradiol.

B) Turner syndrome: documented pre-established diagnosis by karyotype.

  • Prepubertal status according to Tanner Pre-established history of normal thyroid function or adequate substitution for at least 3 months.
  • Weight for stature within the population specific normal range (>5th and \<95th percentiles) for gender Willingness and ability to comply with the protocol for the duration of the study.
  • Parent's or guardian's written , given before any study related procedure that is not part of the subject's normal medical care, with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. If the child is old enough to read and write, a separate assent form will be given.

Exclusion criteria

Exclusion Criteria:

  • Acquired GHD due to central nervous system tumour, trauma, infection, infiltration (documented by imaging), and history of irradiation or cranial surgery
  • Previous treatment with GH, growth hormone-releasing hormone (GHRH), anabolic steroids or any treatment affecting growth.
  • Previous treatment with , except in case of topical or inhaled corticosteroid administration for atopic disease. Corticosteroids for hormonal substitution are also allowed if the condition and the treatment regimen have been stable for at least 3 months.
  • Severe associated pathology affecting growth such as malnutrition, malabsorption, or bone dysplasia.
  • Chronic severe kidney disease.
  • Chronic severe liver disease.
  • Chronic infectious disease.
  • Acute or severe illness during the previous 6 months.
  • Significant concomitant illness that would interfere with participation or assessment in this study.
  • Active (except non-melanomatous skin malignancies that have undergone surgical excision and/or , diagnosis and treatment to resolution)
  • History or active Idiopathic intra-cranial hypertension (benign intracranial hypertension or pseudo-tumor cerebri).
  • Diabetes Mellitus type I \& II.
  • Any disease.
  • Previous screening failure in this study.
  • Use of an drug or participation in another clinical study within the last three months.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
318 participants (actual)

Study arms

  • Experimental
    Turner Syndrome (TS)

    Drug: Saizen

  • Experimental
    Growth Hormone Deficiency (GHD)

    Drug: Saizen

Interventions

  • DrugHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month

  • DrugHuman Growth HormoneStudies of Human Growth HormoneHuman Growth Hormone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) at Month 1

    IGF-1 SDS was calculated using the Elmlinger reference method. Change in within subject IGF-1 levels (standard deviation scores) at Month 1 from Baseline was assessed. Descriptive statistics were determined for the Baseline and Month 1 assessments, and also for the level of change between these two assessments. If either the Baseline or Month 1 IGF-1 level was missing, then the within-subject change in IGF-1 was assumed to be missing.

    Time frame: Baseline, Month 1

Secondary outcomes

  1. Change From Baseline in Insulin-like Growth Factor Binding Protein - 3 (IGFBP-3) Level at Month 1

    Time frame: Baseline, Month 1

  2. Change From Baseline in Fasting Glucose Levels at Month 1

    Time frame: Baseline, Month 1

  3. Change From Baseline in Fasting Insulin Levels at Month 1

    Time frame: Baseline, Month 1

  4. Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Month 1

    HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter \[pmol/L\]) \* fasting plasma glucose (millimole/liter \[mmol/L\]) divided by 22.5.

    Time frame: Baseline, Month 1

  5. Change From Baseline in Bone Alkaline Phosphatase Levels at Month 1

    Time frame: Baseline, Month 1

07

Results

Posted Mar 20, 2018
Limitations and caveats
Limitations of the trial were short duration of the study treatment, and relatively small sample size

Participant flow

First informed consent date: May 2005. Clinical data cutoff date: Oct 2007, Study completion date: Sep 2007.

Participant flow — Overall Study
MilestoneTurner Syndrome (TS)Growth Hormone Deficiency (GHD)
Started149169
Completed147167
Not completed22
Withdrew: Adverse event10
Withdrew: Other12

Outcome measures

PrimaryChange From Baseline in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) at Month 1

IGF-1 SDS was calculated using the Elmlinger reference method. Change in within subject IGF-1 levels (standard deviation scores) at Month 1 from Baseline was assessed. Descriptive statistics were determined for the Baseline and Month 1 assessments, and also for the level of change between these two assessments. If either the Baseline or Month 1 IGF-1 level was missing, then the within-subject change in IGF-1 was assumed to be missing.

Time frame:
Baseline, Month 1
Reported as:
Mean · Standard deviation score (SDS)
Change From Baseline in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) at Month 1
Standard deviation score (SDS)Turner Syndrome (TS)Growth Hormone Deficiency (GHD)
Change From Baseline in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) at Month 11.7692 ± 1.18891.4007 ± 0.9811
Statistical analysis
  • Turner Syndrome (TS) vs Growth Hormone Deficiency (GHD) · Wilcoxon (Mann-Whitney) · p = <0.0001
SecondaryChange From Baseline in Insulin-like Growth Factor Binding Protein - 3 (IGFBP-3) Level at Month 1
Time frame:
Baseline, Month 1
Reported as:
Mean · milligram per liter (mg/L)
Change From Baseline in Insulin-like Growth Factor Binding Protein - 3 (IGFBP-3) Level at Month 1
milligram per liter (mg/L)Turner Syndrome (TS)Growth Hormone Deficiency (GHD)
Change From Baseline in Insulin-like Growth Factor Binding Protein - 3 (IGFBP-3) Level at Month 10.86 ± 0.960.69 ± 0.81
SecondaryChange From Baseline in Fasting Glucose Levels at Month 1
Time frame:
Baseline, Month 1
Reported as:
Mean · millimoles per liter (mmol/L)
Change From Baseline in Fasting Glucose Levels at Month 1
millimoles per liter (mmol/L)Turner Syndrome (TS)Growth Hormone Deficiency (GHD)
Change From Baseline in Fasting Glucose Levels at Month 10.22 ± 0.80.13 ± 0.65
SecondaryChange From Baseline in Fasting Insulin Levels at Month 1
Time frame:
Baseline, Month 1
Reported as:
Mean · picomole per liter (pmol/L)
Change From Baseline in Fasting Insulin Levels at Month 1
picomole per liter (pmol/L)Turner Syndrome (TS)Growth Hormone Deficiency (GHD)
Change From Baseline in Fasting Insulin Levels at Month 147.7 ± 177.226.9 ± 79.8
SecondaryChange From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Month 1

HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter \[pmol/L\]) \* fasting plasma glucose (millimole/liter \[mmol/L\]) divided by 22.5.

Time frame:
Baseline, Month 1
Reported as:
Mean · picomole per liter *millimole per liter
Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Month 1
picomole per liter *millimole per literTurner Syndrome (TS)Growth Hormone Deficiency (GHD)
Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Month 12.132 ± 10.2961.061 ± 3.885
SecondaryChange From Baseline in Bone Alkaline Phosphatase Levels at Month 1
Time frame:
Baseline, Month 1
Reported as:
Mean · Units per liter (U/L)
Change From Baseline in Bone Alkaline Phosphatase Levels at Month 1
Units per liter (U/L)Turner Syndrome (TS)Growth Hormone Deficiency (GHD)
Change From Baseline in Bone Alkaline Phosphatase Levels at Month 121.13 ± 80.6814.78 ± 25.23

Adverse events

Collected over Adverse events were captured from first dose until at least 4 weeks following the last SAIZEN® administration or the post-treatment visit, whichever represented the longer period (up to a maximum of 2 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Turner Syndrome (TS)—0/149 (0%)36/149 (24.2%)
Growth Hormone Deficiency (GHD)—1/169 (0.6%)51/169 (30.2%)
Most frequent serious events
Most frequent serious events
EventTurner Syndrome (TS)Growth Hormone Deficiency (GHD)
Tonsillitis streptococcalInfections and infestations0/1491/169
Most frequent other events
Showing 10 of 51
Most frequent other events
EventTurner Syndrome (TS)Growth Hormone Deficiency (GHD)
HeadacheNervous system disorders8/14912/169
PyrexiaGeneral disorders6/1499/169
CoughRespiratory, thoracic and mediastinal disorders5/1492/169
NasopharyngitisInfections and infestations4/1492/169
VomitingGastrointestinal disorders3/1494/169
Productive coughRespiratory, thoracic and mediastinal disorders3/1490/169
Upper respiratory tract infectionInfections and infestations3/1492/169
DiarrhoeaGastrointestinal disorders1/1493/169
DizzinessNervous system disorders2/1491/169
Ear infectionInfections and infestations2/1490/169

Baseline characteristics

Age, Continuous
Age, Continuous(years)Turner Syndrome (TS)Growth Hormone Deficiency (GHD)Total
Mean9.3 ± 4.088.94 ± 3.179.11 ± 3.62
Sex: Female, Male
Sex: Female, Male(Participants)Turner Syndrome (TS)Growth Hormone Deficiency (GHD)Total
Female14963212
Male0106106
08

Study locations

13 sites
  • Local Medical Information Office
    Buenos Aires, Argentina
  • Local Medical Information Office
    Sydney, Australia
  • Local Medical Information Office
    Vienna, Austria
  • Local Medical Information Office
    Mississauga, Canada
  • Local Medical InformationOffice
    Paris, France
  • Local Medical Information Office
    Munich, Germany
  • Local Medical Information Office
    Rome, Italy
  • Local Medical Information Office
    Oslo, Norway
  • Local Medical Information Office
    Russia, Russian Federation
  • Local Medical Information Office
    Singapore, Singapore
  • Local Medical Information Office
    Madrid, Spain
  • Local Medical Information Office
    Stockholm, Sweden
  • Local Medical Information Office
    Feltham, United Kingdom
09

References and documents

Publications

  • Stevens A, Clayton P, Tato L, Yoo HW, Rodriguez-Arnao MD, Skorodok J, Ambler GR, Zignani M, Zieschang J, Della Corte G, Destenaves B, Champigneulle A, Raelson J, Chatelain P. Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome. Pharmacogenomics J. 2014 Feb;14(1):54-62. doi: 10.1038/tpj.2013.14. Epub 2013 Apr 9. PubMed 23567489 ↗
  • Stevens A, Murray P, De Leonibus C, Garner T, Koledova E, Ambler G, Kapelari K, Binder G, Maghnie M, Zucchini S, Bashnina E, Skorodok J, Yeste D, Belgorosky A, Siguero JL, Coutant R, Vangsoy-Hansen E, Hagenas L, Dahlgren J, Deal C, Chatelain P, Clayton P. Gene expression signatures predict response to therapy with growth hormone. Pharmacogenomics J. 2021 Oct;21(5):594-607. doi: 10.1038/s41397-021-00237-5. Epub 2021 May 27. PubMed 34045667 ↗
  • Murray PG, Stevens A, De Leonibus C, Koledova E, Chatelain P, Clayton PE. Transcriptomics and machine learning predict diagnosis and severity of growth hormone deficiency. JCI Insight. 2018 Apr 5;3(7):e93247. doi: 10.1172/jci.insight.93247. eCollection 2018 Apr 5. PubMed 29618660 ↗
  • Valsesia A, Chatelain P, Stevens A, Peterkova VA, Belgorosky A, Maghnie M, Antoniazzi F, Koledova E, Wojcik J, Farmer P, Destenaves B, Clayton P; PREDICT Investigator group. GH deficiency status combined with GH receptor polymorphism affects response to GH in children. Eur J Endocrinol. 2015 Dec;173(6):777-89. doi: 10.1530/EJE-15-0474. Epub 2015 Sep 4. PubMed 26340968 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2005 to primary completion in Sep 2007, 27 months.

Results were first posted in Mar 2018, 10 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2005
First posted
Nov 21, 2005
StartActual
May 31, 2005
Primary completionActual
Sep 30, 2007
CompletionActual
Sep 30, 2007
Results first posted
Mar 20, 2018
Last update
Jun 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00256126
Responsible party
Sponsor
First posted
Nov 21, 2005
Start date
May 31, 2005
Primary completion
Sep 30, 2007
Completion
Sep 30, 2007
Results posted
Mar 20, 2018
Last update
Jun 26, 2018

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion